Clinical trial · Interventional
MR-guided Tumour Boost
MR-guided Tumour Boost With Stereotactic Body Radiotherapy in Prostate Cancer
NCT05364229CI-TRIAL-00104757MRL-Boost PCactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MR-guided Radiotherapy Boost | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MR-guided Tumour Boost with SBRT
- description
- MR-guided radiotherapy boost to MRI visible tumour
- interventionNames
- Radiation: MR-guided Radiotherapy Boost
Primary outcomes (1)
- measure
- Feasibility of MR-guided Linear Acceleratorfor tumour-targeted intra-prostatic dose escalation as boost
- timeFrame
- Baseline
- description
- Total proportion of patients achieving predefined dosimetric parameters: PTV V100, PTV D90, Urethra V105, Rectum V75, Bladder V75
Secondary outcomes (3)
- measure
- Acute Toxicity
- timeFrame
- Baseline to 5-year follow-up
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically-proven localized prostate cancer. * Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor) * Low-risk: cT1-T2a, PSA \<10, and Gleason score 6 * Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7 * High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7 * Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume * Planned for EBRT (+/- ADT) * ECOG 0 or 1 * 18 years of age or older * Ability to provide written informed consent to participate in the study Exclusion Criteria: * Prior radiotherapy to pelvis * Radiological evidence of regional or distant metastases at the discretion of the treating physician. * Active ulcerative colitis or Crohn's Disease, at discretion of treating physician * Ataxia Telangectasia and SLE * Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury * Severe claustrophobia
References
Publications (0)
Data not yet available
No reference posted for this study.